|
Transaction Information
ROTH Capital Partners acted as
Financial Advisor to
Achillion Pharmaceuticals, Inc. (“Achillion” or the “Company”)
|
Client Information
Achillion is an innovative
pharmaceutical company dedicated to bringing new treatments to patients with
infectious disease. The Company's focus is currently on developing four
distinct clinical candidates, across three separate classes, for the treatment
of chronic hepatitis C infection. First, Achillion is developing ACH-1625, a
proprietary NS3 protease inhibitor with proven efficacy, safety/tolerability and
once-daily dosing. The Company is also developing ACH-2684, a pan-genotypic
inhibitor of HCV NS3 protease with pico-molar potency, and ACH-2928, an
inhibitor of HCV NS5A with excellent potency and synergistic activity with HCV
protease inhibitors, each of which is expected to enter the clinic in the first
part of 2011. Finally, Achillion is developing ACH-1095, a candidate from a
unique class of compounds called NS4A antagonists which have been demonstrated
to be synergistic with other HCV inhibitors. Achillion also has a proprietary
series of candidates for the treatment of serious, resistant bacterial
infections. Each of these programs was discovered through Achillion's own
proprietary internal drug discovery efforts. (Source: Press Releases, Company
Website).
ROTH Capital Partners
ROTH
Capital Partners, LLC (ROTH), is a relationship-driven full service investment
bank focused on identifying opportunities for institutional investors in
U.S.-listed equity securities of companies based in the U.S. and China.
Headquartered in Newport Beach, CA, with offices throughout the U.S. and a
Shanghai Representative Office, the employee-owned firm provides analytical
research, trading, capital raising, and business combination advisory services.
ROTH seeks to implement innovative financing strategies to efficiently meet the
liquidity and valuation requirements of both its corporate and institutional
investor clients.
|
